AP NEWS
Press release content from Business Wire. The AP news staff was not involved in its creation.
PRESS RELEASE: Paid content from Business Wire
Press release content from Business Wire. The AP news staff was not involved in its creation.

Gossamer Bio Announces Data Presentations at the American College of Allergy, Asthma and Immunology Annual Scientific Meeting 2019

November 8, 2019

SAN DIEGO--(BUSINESS WIRE)--Nov 8, 2019--

Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology, today announced that two abstracts supporting GB001, the Company’s oral DP2 antagonist for the treatment of asthma and allergic disease, have been accepted for presentation at the American College of Allergy, Asthma and Immunology (ACAAI) Annual Scientific Meeting 2019 being held November 7- 11 in Houston, Texas.

Details for the ACAAI presentations are as follows:

 

Session Title:

E-posters – Meet the Authors: Session 1

Abstract Number:

P210

Abstract Title:

Indicators of Asthma Exacerbation Before Initiation of Biologic Therapy: A Real-world Experience

Presenter Name:

Hector Ortega, MD, ScD

Presentation Date/Time:

Friday, November 8; 5:30 – 5:45 p.m. CT

Location:

George R. Brown Convention Center, Halls A3 & B3 (Level 3), Monitor 8

 

Session Title:

E-posters – Meet the Authors: Session 2

Abstract Number:

P213

Abstract Title:

Phase 2 study results of DP2-antagonist GB001 on asthma worsening and other asthma control markers

Presenter Name:

Hector Ortega, MD, ScD

Presentation Date/Time:

Saturday, November 9; 11:45 a.m. – 12:00 p.m. CT

Location:

George R. Brown Convention Center, Halls A3 & B3 (Level 3), Monitor 8

About Gossamer Bio

Gossamer Bio is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology. Its goal is to be an industry leader in each of these therapeutic areas and to enhance and extend the lives of patients suffering from such diseases.

View source version on businesswire.com:https://www.businesswire.com/news/home/20191108005080/en/

CONTACT: For Investors:

Argot Partners

Tel 212.600.1902

gossamerbio@argotpartners.comFor Media:

Argot Partners

David Rosen

Tel 212.600.1902

david.rosen@argotpartners.com

KEYWORD: UNITED STATES NORTH AMERICA CALIFORNIA TEXAS

INDUSTRY KEYWORD: ONCOLOGY HEALTH OTHER HEALTH GENERAL HEALTH PHARMACEUTICAL BIOTECHNOLOGY

SOURCE: Gossamer Bio, Inc.

Copyright Business Wire 2019.

PUB: 11/08/2019 07:00 AM/DISC: 11/08/2019 07:01 AM

http://www.businesswire.com/news/home/20191108005080/en